CRISPR Study Identifies Two Genes as Predictive Biomarkers for Cancer Immunotherapy Response
Key Insights
Researchers at the Wellcome Sanger Institute (search) discovered that deletion of CHD1 (search) and MAP3K7 (search) genes makes cancer (search) cells more vulnerable to immune attack and improves immunotherapy (search) response.
The study used a novel CRISPR co-culture method to identify genes that regulate immune sensitivity, finding that patients with low expression of these genes are more likely to benefit from immunotherapy (search).
Analysis of patient data confirmed that tumors with reduced CHD1 (search) or MAP3K7 (search) expression showed better immunotherapy (search) responses, potentially enabling more personalized cancer (search) treatment approaches.
Researchers have identified two genes that could serve as predictive biomarkers for cancer (search) immunotherapy (search) response, potentially addressing one of oncology's most pressing challenges: determining which patients will benefit from immune-based treatments. The study, published in Cell Reports Medicine on January 20, reveals that deletion of CHD1 (search) and MAP3K7 (search) genes significantly enhances tumor vulnerability to immune attack.
Novel CRISPR Approach Reveals Immune Sensitivity Mechanisms
Scientists at the Wellcome Sanger Institute (search), Open Targets (search), Netherlands Cancer Institute (search) and collaborators employed genome-wide CRISPR-Cas9 screening to systematically identify genes that influence immune system effectiveness against cancer (search) cells. The researchers developed an innovative co-culture method where tumor cells and immune cells from the same individual were cultured together to measure immune-mediated cancer cell killing.
"We found that when cancer (search) cells lose two genes, CHD1 (search) and MAP3K7 (search), they become much easier for the immune system to attack, as without these active genes, cancer cells respond very differently to immune signals," said Alex Watterson, co-first author formerly at the Wellcome Sanger Institute (search) and now at the Babraham Institute (search).
Enhanced Immune Vulnerability Through Gene Knockout
The research demonstrated that knocking out either CHD1 (search) or MAP3K7 (search) individually increased cancer (search) cell sensitivity to key immune signals, particularly interferon-gamma (IFN-γ) and direct T-cell attack. When both genes were simultaneously deleted, cancer cells became even more vulnerable to immune destruction, suggesting these genes normally protect tumors from immune recognition.
The loss of CHD1 (search) and MAP3K7 (search) appears to alter how cancer (search) cells respond to inflammatory signals, pushing them toward self-destruction when the immune system is activated. Mouse model studies confirmed these laboratory findings, showing that tumors lacking these genes responded significantly better to immunotherapy (search) and attracted higher levels of cancer-killing immune cells.
Clinical Validation and Therapeutic Implications
Patient data analysis provided crucial clinical validation, revealing that cancers with low CHD1 (search) or MAP3K7 (search) expression levels were more likely to respond to immunotherapy (search). This finding addresses a critical unmet need, as current immunotherapy response rates remain below 35% in solid tumor patients despite the treatment's transformative potential for some patients.
"We saw that patients whose tumours have low expression of these genes are more likely to benefit from immunotherapy (search). In the future, these new biomarkers could guide doctors by predicting who will respond to treatment and enable more personalised cancer (search) care," explained Dr. Matthew Coelho, senior author at the Wellcome Sanger Institute (search) and Open Targets (search).
Addressing Immunotherapy Resistance
The research provides mechanistic insights into immunotherapy (search) resistance, a phenomenon that has puzzled oncologists despite the treatment's success in specific cancer (search) types like melanoma (search) and microsatellite instability (search) (MSI) tumors. MSI cancers respond well to immunotherapy because their defective DNA repair systems create numerous mutations, generating abnormal proteins easily detected by the immune system.
Dr. Mathew Garnett, co-senior author at the Wellcome Sanger Institute (search) and Open Targets (search), emphasized the study's significance: "Immunotherapy (search) can be life-changing for some people with cancer (search), but for many patients it simply doesn't work, and it's been a mystery why that is the case. Understanding the mechanism behind why some tumours respond and others resist treatment is one of the biggest conundrums that our research is one step closer to helping to solve."
Future Directions for Personalized Treatment
The identification of CHD1 (search) and MAP3K7 (search) as biomarkers could enable more precise patient selection for immunotherapy (search), potentially improving treatment outcomes while reducing unnecessary exposure to ineffective therapies. The findings suggest these genes could guide the development of combination approaches or novel therapeutic strategies to enhance immunotherapy effectiveness in broader patient populations.